treatment guidelines

Research in Review

Dose Escalation of CML Treatment Improves Molecular Response Rates

08/02/2017

JCP Editors

Patients with chronic myeloid leukemia (CML) in the chronic phase may achieve molecular response with safe and effective treatment dose escalation, according to a recent study. ----- Related Content CML Mutations...

...

08/02/2017

Journal of Clinical Pathways

Research in Review

CML Treatment Decisions Should Factor in Cardiovascular Disease Risk

07/27/2017

JCP Editors

Cardiovascular disease rates and its associated risks are increased in patients with chronic myelogenous leukemia (CML) treated by community-based oncologists and should impact treatment decisions, according to a...

...

07/27/2017

Journal of Clinical Pathways

Research in Review

Immunotherapy Shows Promise in Rare Type of Lymphoma

07/11/2017

JCP Editors

A recent report demonstrates the promise of programmed death (PD-1) inhibition in improving outcomes for patients with a rare, difficult-to-treat type of lymphoma, published in The New England Journal of Medicine...

A...

07/11/2017

Journal of Clinical Pathways

Research in Review

Best Cost-Effective Option for Breakthrough Cancer Pain Revealed

06/28/2017

JCP Editors

A cost-effectiveness analysis assessed oral fentanyl formulations available for the treatment of breakthrough cancer pain, published in PLOS One (published online June 27, 2017;...

A...

06/28/2017

Journal of Clinical Pathways

Research in Review

Can Active Surveillance Benefit Younger Patients With Prostate Cancer?

06/19/2017

JCP Editors

Research suggests that age can impact the risk of disease progression in low-risk prostate cancer managed with active surveillance, published in the Journal of Clinical Oncology (June 2017;35[17]:1898-1904). Recent...

...

06/19/2017

Journal of Clinical Pathways

Research in Review

Earlier Endpoint May Be Predictive of Lung Cancer Therapy Outcomes

06/16/2017

JCP Editors

A novel intermediate endpoint could be a useful measure in clinical trials for metastatic non-small cell lung cancer (mNSCLC), according to a recent study published in JAMA (published online June 15, 2017;...

A...

06/16/2017

Journal of Clinical Pathways

Research in Review

Personalized Dosing More Cost-Effective for NSCLC Treatment

06/15/2017

JCP Editors

A recent budget analysis evaluated the costs, safety, and efficacy of personalized dosing compared with fixed dosing of standard-of-care treatment for non-small cell lung cancer, presented at the 2017 ASCO Annual...

A...

06/15/2017

Journal of Clinical Pathways

Research in Review

Recent Breast Cancer HER2 Testing Guideline Update Produces Similar Positivity Rate

06/14/2017

JCP Editors

Updates to the 2013 human epidermal growth factor receptor 2 (HER2) testing guideline in breast cancer did not affect the overall positivity rate or the proportion of patients eligible for targeted therapy, according...

...

06/14/2017

Journal of Clinical Pathways

Research in Review

Brain Metastases Resistant to Targeted Therapy Due to Gene Overexpression

06/14/2017

JCP Editors

A novel mechanism responsible for brain metastasis resistance to targeted therapy has been identified, which may help guide treatment strategies, according to a study published in Science Translational Medicine...

A...

06/14/2017

Journal of Clinical Pathways

Research in Review

Combination Therapy Improves Outcomes for Patients With MCL

06/08/2017

JCP Editors

Patients with mantle cell lymphoma (MCL) have increased odds of achieving complete remission after being treated with a combination regimen, according to research presented at the 2017 ASCO Annual Meeting (June 2-6,...

...

06/08/2017

Journal of Clinical Pathways